Generative AI shows potential in pharma for R&D, manufacturing, and supply chains, but regulatory compliance, expertise gaps, and adoption hinder progress.
The global AI drug commercialization market is set to grow at a CAGR of 24% by 2032, revolutionizing drug launches, pricing, and patient engagement worldwide.
Asia-Pacific governments promote biopharma growth through R&D, collaborations, and innovation hubs like Singapore, boosting healthcare and entrepreneurs.
Continuous manufacturing is improving biopharma production, ensuring faster timelines, lower costs, better quality and sustainability in future of healthcare.
The pharmaceutical sector is looking to align MDR and IVDR to make the medical device sector in the EU more seamless and filled with immense opportunities.
